A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights that while biosimilars can reduce costs and improve access for autoimmune disease treatments, patient preferences and characteristics influence switching patterns. Older adults, women, and those with ankylosing spondylitis were more likely to switch back, especially in rural areas. These insights can help clinicians and health plans support patients during biosimilar transitions and build confidence in these therapies.
The European Medicines Agency's CHMP has given a positive opinion recommending approval of AbbVie's upadacitinib for treating severe alopecia areata in adults and adolescents. This recommendation follows Phase 3 trial data showing significant hair re...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending upadacitinib for treating adult and adolescent patients with non-segmental vitiligo, a chronic autoimmune skin disease. Th...
The JPMorgan Equity Premium Income ETF (JEPI) pays monthly distributions currently yielding about 8.3%, but the payment amount fluctuates due to its strategy of selling out-of-the-money call options, which generate premiums that depend on market vola...
The FDA has approved SKYRIZI (risankizumab-rzaa) for treating children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing i...
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
